An in vivo small-molecule drug screen in developing zebrafish larvae identifies dozens of unique chemical modulators capable of reducing atherogenic apolipoprotein B levels.
A sequence-based method dubbed AroMIP predicts the membrane insertion propensities of aromatic-centered motifs, thereby advancing mechanistic understanding of membrane insertion and enriching the tools for studying intrinsically disordered protein (IDP)-membrane association.
